ea0073oc3.1 | Oral Communications 3: Pituitary and Neuroendocrinology | ECE2021
Gadelha Monica
, MarieBex
, Feelders Richard
, Heaney Anthony
, Auchus Laviola
, Gilis-Januszewska Laviola
, Witek Przemyslaw
, Zhanna Belaya
, Zhihong Liao
, Chen Ku Witek
, Carvalho Davide
, Roughton Michael
, Wojna Judi
, Hofstetter Georg
, Pedroncelli Alberto
, Snyder Peter
IntroductionOsilodrostat, a potent, oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD during a Phase III, randomized-withdrawal study. We now report findings from a Phase III study of osilodrostat in patients with CD that featured an initial double-blind, randomized, placebo-controlled period (LINC 4; NCT02697734).MethodsAdults with CD (mUFC > 1.3 &...